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A B S T R A C T
Objectives: The aim of this study was to evaluate the clinical utility of the new bleeding criteria, proposed
by the Bleeding Academic Research Consortium (BARC), compared with the old criteria for determining
the action of physicians in contact with bleeding events, after percutaneous coronary intervention (PCI).
Background: The BARC criteria were independently associated with an increased risk of 1-year mortality
after PCI, and provided a predictive value, in regard to 1-year mortality. The standardized bleeding
deﬁnitions will be expected to help the physician to correctly analyze the bleeding events, to select an
optimal treatment, and to objectively compare the results of multiple trials and registries.
Methods: All the patients undergoing PCI from June to September 2012 were prospectively enrolled.
Patients who experienced a bleeding event were further classiﬁed, based on three different bleeding
severity criteria: BARC, Thrombolysis In Myocardial Infarction (TIMI), and Global Use of Strategies To
Open coronary arteries (GUSTO). The primary outcome was the occurrence of bleeding events requiring
interruption of antiplatelet therapy (IAT) by physicians.
Results: A total of 376 consecutive patients were included in this study. Total bleeding events occurred in
46 patients (12.2%). BARC type 2 bleeding occurred in 30 patients (8.0%); however, TIMI major or minor
bleeding, and GUSTO moderate or severe bleeding occurred in 6 (1.6%) and 11 patients (2.9%),
respectively. Of the 46 patients, 28 (60.9% of patients) required IAT. On receiver-operating characteristic
curve analysis, bleeding deﬁned BARC type 2 effectively predicted IAT, with a sensitivity of 89.3%, and a
speciﬁcity of 98.5% (p < 0.001), compared with TIMI (sensitivity, 21.4%; speciﬁcity, 100%; p < 0.001), and
GUSTO (sensitivity, 39.3%; speciﬁcity, 100%; p < 0.001).
Conclusions: Compared with TIMI and GUSTO, the BARC deﬁnition may be a more useful tool for the
detection of bleeding with clinical relevance, for patients undergoing PCI.
 2014 Japanese College of Cardiology. Published by Elsevier Ltd. All rights reserved.
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The developments of antithrombotic and antiplatelet therapy
have reduced the risk of recurrent ischemic complications and
death, in patients undergoing percutaneous coronary intervention* Corresponding author at: Regional Cardiovascular Center, Dong-A University
Hospital, Division of Cardiology, Department of Internal Medicine, Dong-A
University College of Medicine, 1-3 Ga, Dongdaesin-Dong, Seo-Gu, Busan
602-714, South Korea. Tel.: +82 51 240 2733; fax: +82 51 242 5852.
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0914-5087/ 2014 Japanese College of Cardiology. Published by Elsevier Ltd. All rights(PCI) [1–3]. However, bleeding complications have increased, with
the concurrent use of those drugs [4–6]. Previous studies have
shown that bleeding complications have been associated with
adverse clinical outcomes, in patients with acute coronary
syndrome (ACS), and those undergoing PCI [7–10]. As a result,
bleeding avoidance strategies (BAS), such as radial artery
approach, vascular closure device, and novel antithrombotic
agents, have been developed for patients undergoing PCI, and
have contributed to reducing the risk of bleeding events [11–14].
While the reduction of bleeding events has the potential to
improve clinical outcomes, the variable criteria of bleeding
deﬁnitions make it difﬁcult to interpret the safety of BAS or reserved.
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Recently, a consensus effort by academics, research organizations,
industry, and regulator representatives resulted in the Bleeding
Academic Research Consortium (BARC) suggesting a new objec-
tive: a hierarchically graded, consensus classiﬁcation for bleeding
complications [16]. The BARC criteria are a consensus-based
report, rather than clinically based or laboratory-based assess-
ments. According to previous large clinical trials to evaluate the
validation of the BARC deﬁnition, bleeding complications as
deﬁned by BARC criteria were independently associated with an
increased risk of 1-year mortality after PCI, and provided a
predictive value in regard to 1-year mortality [17–19].
The purpose of this present study was to prospectively compare
the clinical utility of new bleeding criteria and old bleeding
deﬁnitions associated with decision making, for bleeding events in
real-world clinical practice.
Materials and methods
Study population
We prospectively enrolled consecutive patients undergoing PCI
with second-generation drug-eluting stents between June and
September 2012. Patients were excluded, if they had thrombocy-
topenia, or previous history of any bleeding events within the prior
30 days; or if patients had hemodynamic instability, malignancy,
recent trauma or major surgery, including coronary artery bypass
graft (CABG) in the last month; or if patients have been taking
proton pump inhibitors, steroid or non-steroidal anti-inﬂamma-
tory drugs. They underwent clinical examination, including
hemoglobin level, platelet count, serum creatinine, cardiac
enzyme, lipid level, chest X-ray, electrocardiogram, and echocar-
diography.
Clinical endpoint measurements were conducted in-hospital, at
4 weeks, and at 6 months. Hemoglobin or hematocrit levels after
each bleeding event, and hemodynamic status during each
bleeding event were recorded. In the case of multiple bleeding
events, the most severe bleeding episode was considered. The
medical history and data from physical examinations were
recorded by a single examiner. The bleeding severity was assessed
by a trained independent physician. Bleeding data were collected
over telephone interview, for 6 months after being discharged.
Study approval was given by the institutional review board at
Dong-A University Hospital, and consecutive, eligible patients
provided written, informed consent.
Procedures and arterial puncture site management
All the procedures were performed according to the latest
standard guidelines [20]. Sheath sizes of 5–7 French were used for
the percutaneous procedure during the study period. Enrolled
patients were pretreated with 300 mg of clopidogrel. At the
beginning of the procedure, 5000 units of heparin were adminis-
tered intra-arterially, as a routine. Patients were treated with dual
antiplatelet therapy for 6 months and advised to maintain aspirin
(80 mg/day) lifelong. Conventional manual compression was
performed on all study populations, as arterial puncture site
management. If bleeding events occurred during the study period,
the choice of treatment was determined by the patient’s physician.
Study endpoint and deﬁnitions
The primary outcome was the occurrence of bleeding compli-
cations requiring the interruption of antiplatelet therapy (IAT). In
the present study, IAT was deﬁned as either a temporaryinterruption of aspirin and/or a thienopyridine (interruption of
>1 day), or a permanent discontinuation by physician [21].
Patients who experienced a bleeding event were further
classiﬁed, based on three different bleeding severity criteria:
Thrombolysis In Myocardial Infarction (TIMI) [22], Global Use of
Strategies To Open coronary arteries (GUSTO) [23], and the BARC
criteria [16]. A detailed description of these bleeding classiﬁcations
is given in online Table 1. Concurrently, we repeatedly evaluated
bleeding complications for the need for IAT, in all the study
population.
Supplementary Table 1 related to this article can be found, in
the online version, at http://dx.doi.org/10.1016/j.jjcc.2014.06.011.
The secondary outcome of this study was 6-month cardiac
mortality. Deaths were categorized as cardiac, or non-cardiac. All
deaths were considered cardiac, unless an unequivocal non-
cardiac cause could be established.
Statistical analysis
Data are presented as mean  SD for continuous variables, or as
numbers (%) for categorical variables, as appropriate. Differences
between continuous variables in patients who did, and did not,
experience bleeding events, were compared, using the Student t test
or Mann–Whitney test, depending on the results of normality testing
by the Shapiro–Wilk test. Chi-square test was used to compare the
categorical variables. Odds ratios (ORs) and conﬁdence intervals (CIs)
were derived by use of the linear logistic regression mode, to estimate
which predictors identiﬁed in the univariate analysis were signiﬁ-
cantly related to the primary outcome. Sensitivity, speciﬁcity, and
accuracy with respect to bleeding requiring IAT were calculated for
BARC, TIMI, and GUSTO criteria, with the use of standard formulae,
and compared with the McNemar test. To assess cut-off values of
three bleeding criteria in need for IAT, receiver-operating character-
istic (ROC) curve analysis was used. The cut-off values were selected
as those with the maximal sum of sensitivity and speciﬁcity. Chi-
square test and Fisher’s exact test were used to evaluate the
association between the three bleeding deﬁnitions, and bleeding
requiring IAT. All data were analyzed by IBM SPSS statistics software,
version 20 (SPSS Inc., Chicago, IL, USA). A probability value of p < 0.05
was taken as a cut-off value for statistical signiﬁcance.
Results
Baseline characteristics
A total of 376 patients were recruited in this study. All the
patients were clinically followed up. Table 1 shows baseline
characteristics of the study populations. The proportion of women
and ACS patients was 147 patients (39.1%) and 214 patients
(56.9%), respectively. Twenty-three patients (6.1%) were diagnosed
to have ST-elevation myocardial infarction. The vascular access site
was usually radial (86.2%). The overall population was classiﬁed
into bleeding and non-bleeding groups, according to the bleeding
events.
Bleeding events
Total bleeding events occurred in 46 patients (12.2%) at 6-
month follow-up. The most common bleeding events were
hematoma or oozing in puncture site (65%) in the 46 bleeding
patients (Table 2). Other bleeding complications were gastroin-
testinal bleeding (13%), gross hematuria (10%), upper airway
bleeding (4%), pericardial effusion (4%), and aortic dissection
(2.5%). Nine patients (19%) underwent blood transfusion, due to
large blood loss, or lowering of hemoglobin level (3 g/dL).
Differences between the ‘‘bleeding group’’ and ‘‘non-bleeding
Table 1
Comparison of clinical characteristics in the study population.
Characteristics Total patients Bleeding group Non-bleeding group p-valuea
n = 46 n = 330
Age, years 63.41  11.1 69.5  10.1 62.5  11.0 0.001
Women, n (%) 147 (39.1%) 26 (56%) 121 (37%) 0.015
Diabetes mellitus, n (%) 125 (33.2%) 21 (46%) 104 (32%) 0.066
Arterial hypertension, n (%) 189 (50.3%) 29 (63%) 160 (48%) 0.083
Current smoking, n (%) 135 (37.0%) 9 (20%) 130 (39%) 0.009
Hyperlipidemia, n (%) 142 (37.8%) 17 (37%) 125 (38%) 0.521
Previous myocardial infarction, n (%) 84 (22.3%) 11 (24%) 73 (22%) 0.85
Acute coronary syndrome, n (%) 214 (56.9%) 35 (76%) 179 (54%) 0.006
Elevated troponin I (>0.3 g/L) 108 (28.7%) 23 (50%) 85 (26%) 0.001
Serum creatinine, mg/dL 1.1  1.0 1.5  1.7 1.0  0.8 0.049
Serum hemoglobin, g/dL 13.3  1.7 12.4  1.5 13.4  1.6 0.001
Platelet count (109/L) 218.3  58.7 230.7  70.4 216.5  56.8 0.197
Left ventricular ejection fraction, % 56.0  10.1 52.5  12.7 56.5  9.6 0.044
Multivessel disease (>2-vessel disease), n (%) 113 (30.1%) 24 (52%) 89 (27%) 0.001
Procedure time, min 45.3  28.8 62.3  32.8 43.0  27.3 <0 .001
Contrast dose, mL 169.9  80.8 207.8  105.2 164.6  75.4 0.001
Catheter size (7 French), n (%) 14 (3.7%) 5 (11%) 9 (3%) 0.019
Trans-femoral approach, n (%) 48 (12.8%) 17 (37%) 31 (9%) <0.001
Hospitalization period after PCI 3.65  2.9 6.67  5.9 3.23  1.9 <0.001
Short term mortality (for 6 months) 8 (2.1%) 8 (17.4%) 0 <0.001
Values are n (%) or mean  SD.
PCI, percutaneous coronary intervention.
a Bleeding group vs non-bleeding group.
Table 2
Characteristics of bleeding complications.
Characteristics Bleeding events
requiring interruption
of antiplatelet therapy
Bleeding events not
requiring interruption
of antiplatelet therapy
n = 28 n = 18
Hematoma, or oozing 13 17
Blood transfusion 9 0
Gastrointestinal bleeding 5 1
Gross hematuria 5 0
Upper airway bleeding 2 0
Pericardial effusion 2 0
Aortic dissection 1 0
Fig. 1. Comparison of bleeding events by the three different criteria. TIMI,
Thrombolysis In Myocardial Infarction; GUSTO, Global Use of Strategies To Open
coronary arteries; BARC, Bleeding Academic Research Consortium.
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(Table 1). Compared with the ‘‘non-bleeding group’’, the ‘‘bleeding
group’’ showed older age, higher levels of cardiac troponin and
serum creatinine, lower left ventricular ejection fraction in
echocardiography, more common use of trans-femoral approach,
higher proportion of multivessel disease, and longer procedure
time. The incidence of bleeding complications is shown in Fig. 1,
according to each deﬁnition. Bleeding events occurred in 6 patients
(1.6%), according to the TIMI minor and major deﬁnition; 11
patients (2.9%), according to the GUSTO moderate and severe
criteria; and 30 patients (8.0%), according to the BARC type 2
bleeding deﬁnition.
Bleeding requiring interruption of antiplatelet therapy
Bleeding requiring IAT was identiﬁed in 28 (60.8%) of the
patients with bleeding events. Table 3 presents clinical character-
istics of bleeding patients in regard to IAT. Bleeding patients who
required IAT showed lower left ventricular ejection fraction, and
longer procedure time and hospitalization period. Table 4 proposes
independent baseline predictors of bleeding events requiring IAT.
Trans-femoral approach (ORs, 5.564; 95% CI 1.820–17.013;
p = 0.003) and long procedure time (60 min) (ORs, 6.907; 95%
CI 2.531–18.849; p < 0.001) were the most powerful predictors of
bleeding events requiring IAT. Sensitivity, speciﬁcity, and accuracy
of bleeding complications as deﬁned by BARC, TIMI, and GUSTO,with respect to bleeding that needs IAT, are presented in Table 5.
BARC type 2 bleeding was more sensitive (89.3%) than TIMI
minor and major (21.4%), or GUSTO moderate and severe (39.3%)
bleeding, in regard to bleeding events requiring IAT. In ROC curve
analyses, we found that BARC 2 effectively predicted bleeding
events requiring IAT, with a sensitivity of 89.3%, and a speciﬁcity of
98.5% (p < 0.001; area under the curve = 0.993) (Fig. 2).
Short-term mortality
Short-term mortality status assessment was completed in all
patients. Over the follow-up period, all mortality (eight patients
died of a cardiac cause) occurred in the bleeding group. Five of
them died from heart failure and three patients died from stent
thrombosis. Bleeding was independently associated with an
increase in short-term mortality (p < 0.001). Of them, six patients
died in the population with bleeding events of need for IAT. Among
Table 3
Comparison of bleeding patients, with regard to interruption of antiplatelet therapy.
Characteristics Bleeding patients Bleeding events requiring IAT Bleeding events not requiring IAT p-valuea
n = 46 n = 28 n = 18
Age, years 69.5  10.1 70.6  9.9 67.7  10.3 0.343
Women, n (%) 26 (56.5%) 14 (50.0%) 12 (66.7%) 0.364
Diabetes mellitus, n (%) 21 (45.7%) 13 (46.4%) 8 (44.4%) 0.569
Arterial hypertension, n (%) 29 (63%) 17 (60.7%) 12 (66.7) 0.761
Current smoking, n (%) 9 (19.6%) 7 (25.0%) 2 (11.1%) 0.448
Hyperlipidemia, n (%) 17 (37%) 9 (32.1%) 8 (44.4%) 0.533
Previous myocardial infarction, n (%) 11 (23.9%) 7 (25.0%) 4 (22.2%) 0.560
Acute coronary syndrome, n (%) 35 (76.1%) 24 (85.7%) 11 (61.1%) 0.080
Elevated troponin I (>0.3 g/L), n (%) 23 (50%) 17 (60.7%) 6 (33.3%) 0.130
Left ventricular ejection fraction, % 52.5  12.7 48.9  14.2 58.1  6.7 0.006
Multivessel disease (>2-vessel disease) 24 (52.2%) 18 (64.3%) 6 (33.3%) 0.069
Procedure time, min 62.3  32.8 73.2  37.1 45.3  13.0 0.004
Contrast dose, mL 207.8  105.2 228.9  117.0 175.0  75.2 0.064
Catheter size (7 French), n (%) 5 (10.9%) 3 (10.7%) 2 (11.1%) 0.659
Trans-femoral approach, n (%) 17 (41.3%) 14 (50%) 5 (27.8%) 0.220
Hospitalization period after PCI 6.67  5.9 8.5  6.8 3.9  1.8 0.002
TIMI (major + minor), n (%) 6 (13.0%) 6 (21.4%) 0 (0%) 0.068
GUSTO (severe + moderate), n (%) 11 (23.9%) 11 (39.3%) 0 (0%) 0.003
BARC (type 2), n (%) 30 (65.2%) 25 (89.3%) 5 (27.8%) <0.001
Short term mortality (for 6 months), n (%) 8 (17.4%) 6 (21.4%) 2 (11.1%) 0.453
Values are n (%) or mean  SD.
IAT, interruption of antiplatelet therapy; PCI, percutaneous coronary intervention; TIMI, Thrombolysis In Myocardial Infarction; GUSTO, Global Use of Strategies To Open
coronary arteries; BARC, Bleeding Academic Research Consortium.
a Medical care action group vs non-medical care action group.
Table 4
Independent baseline predictors of bleeding events requiring interruption of
antiplatelet therapy.
Characteristics Odds ratio (95% CI) p-value
Age  65 years 3.489 (1.122–10.851) 0.031
Acute coronary syndrome 2.180 (0.529–8.981) 0.281
Elevated troponin I (>0.3 g/L) 1.205 (0.393–3.691) 0.744
Serum creatinine >1.2 (mg/dL) 2.041 (0.698–5.966) 0.193
Trans-femoral approach 5.564 (1.820–17.013) 0.003
Procedure time, (60 min) 6.907 (2.531–18.849) <0.001
Multi-vessel disease (>2-vessel disease) 1.671 (0.594–4.704) 0.331
CI, conﬁdence interval.
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no signiﬁcant difference in 6-month cardiac mortality (ORs, 2.182;
95% CI 0.389–12.246; p = 0.453) (Table 3).
Discussion
As the use of PCI with dual antiplatelet therapy has increased,
bleeding complications are an important issue for patients andTable 5
Predictivity of 3 bleeding deﬁnitions, with regard to interruption of antiplatelet therap
Primary end pointa BARC TIMI 
Type 3 Major 
Sensitivity 46.4% 7.1% 
Speciﬁcity 100% 100% 
Accuracy 98.7% 93.1% 
Primary end point BARC TIMI 
Type 2 Major plus minor
Sensitivity 89.3% 21.4% 
Speciﬁcity 98.5% 100% 
Accuracy 97.9% 94.1% 
Data are number or percentage (%).
TIMI, Thrombolysis In Myocardial Infarction; GUSTO, Global Use of Strategies To Ope
a Number of patients = 28.
b BARC type 2 vs TIMI.
c BARC type 2 vs GUSTO.physicians. Bleeding complications after PCI or anti-thrombotic
treatment are closely associated with mortality and morbidity
[24,25]. Therefore, patients undergoing PCI should be monitored
for clinically relevant bleeding, such as bleeding events requiring
the interruption of antiplatelet therapy, any transfusion, and all
invasive procedures and medication for bleeding control. For these
reasons, proper bleeding assessments are needed.
Several deﬁnitions of bleeding complications have been
developed, to determine the severity of bleeding. Among them,
TIMI and GUSTO bleeding criteria have been most commonly used
in cardiovascular studies for decades. The former deﬁnition was
predominantly laboratory driven, while the latter is mainly a
clinically driven scale. TIMI and GUSTO deﬁnitions were limited to
capture the bleeding with clinical relevance [26–28], because they
have evolved to represent a broader range of bleeding categories.
For example, there might be different clinical conditions in
patients with TIMI minimal or GUSTO mild bleeding, which could
not provide any information on whether medical intervention
would be necessary, or antiplatelet agents should be interrupted.
Consequently, they are insufﬁcient to properly guide the action of
the physician in contact with bleeding events. Several clinical trialsy.
GUSTO p-valueb p-valuec
Severe
3.6% <0.001 <0.001
100% – –
92.8% <0.001 <0.001
GUSTO p-valueb p-valuec
 Severe plus moderate
39.3% <0.001 <0.001
100% <0.001 <0.001
95.5% <0.001 <0.001
n coronary arteries; BARC, Bleeding Academic Research Consortium.
Fig. 2. The receiver-operating characteristics curve is depicted for primary outcome,
in relation to Bleeding Academic Research Consortium (BARC), Global Use of
Strategies To Open coronary arteries (GUSTO), and Thrombolysis in Myocardial
Infarction (TIMI).
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GUSTO deﬁnitions [29,30], have modiﬁed these components
[31,32], and have developed their own deﬁnition [25,26], for
analyzing the bleeding complications.
Recently, BARC proposed a new objective, a hierarchically
graded bleeding deﬁnition for standardized bleeding complica-
tions [16]. The standardized bleeding deﬁnition will be expected to
help the physician to correctly analyze the bleeding events, to
select an optimal treatment, and to objectively compare the results
of multiple trials and registries. Recent trials have demonstrated
that the BARC deﬁnition of bleeding was suggested to have a
predictive value in regard to 1-year mortality that is comparable to
that provided by traditional bleeding deﬁnitions [17–19].
In this prospective study, we investigated the clinical utility of
the BARC bleeding deﬁnition aimed at capturing the bleeding that
needs IAT, compared with the TIMI and GUSTO criteria, in patients
with PCI. When using the deﬁnition of BARC, BARC 2 bleeding
was able to discriminate bleeding patients with, and without,
requiring IAT. It means the BARC deﬁnition might be useful for
clinical decisions about bleeding complications. This result would
be driven by the distinctiveness of BARC. First, BARC criteria
classify bleeding events at full length, from minor to major
bleeding. In particular, BARC criteria divide minor bleeding events
into type 1 (not requiring intervention), and type 2 (requiring
intervention or medical evaluation) classes. The detailed identiﬁ-
cation and increased number of bleeding events might represent
better sensitivity, compared with the old criteria, in regard to the
prediction of mortality and signiﬁcant medical treatment. Second,
the BARC deﬁnition proposes an objective, hierarchically graded,
and balanced combination of laboratory-based and clinically based
classiﬁcation for bleeding. Therefore, the BARC criteria will be
more practical, objective, and easy to use, compared with the old
criteria, in clinical trials, and in real clinical practice.
Our study also showed that the trans-femoral approach, use of
large sheath (7 French), and long procedure time were associated
with more bleeding complications, as previous studies reported
[33,34]. In particular, the trans-femoral approach and long
procedure time were most powerful independent baselinepredictors of bleeding events requiring IAT. These results suggest
that radial access and shorter procedure time for PCI would have
the potential advantages of reduced bleeding events in the real
clinical world.
We performed a statistical analysis, to determine whether
bleeding was independently associated with an increase in short-
term mortality. The present study demonstrated that bleeding
complications after PCI were closely associated with substantial
mortality, as previous studies reported [9,17,24,35]. In our data,
the bleeding group showed older age, lower left ventricular
ejection fraction, higher level of troponin I and creatinine, and
more complex coronary lesions, compared with the non-bleeding
group. These results showed that patients who bled were sicker
than those who did not bleed.
Limitations
There are several limitations to this study that should be
addressed. The ﬁrst and major limitations were the small sample
size and the possible selection bias. The sample size of 376 with 28
patients meeting our ‘‘IAT’’ criterion is far too small to draw
inferences about predictors of bleeding. This should be analyzed by
multivariate analysis from a larger population. Second was the
short-term follow-up period, although the purpose of this study
was not to establish a prognostic validation, but clinical utility.
These limitations could lead to an underestimation of the number
of bleeding events. Third, clinical diagnosis of the population was
heterogeneous. However, we prospectively and consecutively
recruited patients undergoing PCI, and thus believe that our
patients are representative of the real PCI population seen in
clinical practice. Fourth, there was no assessment of the activated
clotting time, or platelet reactivity units. Instead, all the patients
were anticoagulated with the exact same doses of heparin, and the
antiplatelet therapy was also identical.
Conclusions
In conclusion, the BARC criteria are more sensitive than the TIMI
or GUSTO deﬁnitions, in regard to the detection of bleeding with
clinical relevance, in real world clinical practice. The results of our
study suggest that BARC may represent an objective clinical tool,
which could identify those patients with bleeding complications,
who would potentially beneﬁt, by helping clinicians to make
judicious decisions.
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